Mylan Inc (MYL.OQ)
23.64USD
11:17am EDT
$0.00 (+0.00%)
$23.64
$23.59
$23.74
$23.55
252,498
--
--
--
MYL.OQ
About
Overall
| Beta: | 0.85 |
| Market Cap (Mil.): | $9,598.43 |
| Shares Outstanding (Mil.): | 405.89 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| MYL.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 18.34 | 29.84 | 28.43 |
| EPS (TTM): | 1.29 | -- | -- |
| ROI: | 5.88 | 4.18 | 4.21 |
| ROE: | 15.70 | 4.88 | 4.35 |
Mylan, Pfizer settle patent suit on generic Detrol LA
- Mylan Inc said it settled with Pfizer Inc a lawsuit that accused it of infringing patents on overactive bladder drug Detrol LA.
Mylan, Pfizer settle patent suit on generic Detrol LA
Sept 7 - Mylan Inc said it settled with Pfizer Inc a lawsuit that accused it of infringing patents on overactive bladder drug Detrol LA.
UPDATE 1-US FDA approves generic versions of Merck's Singulair
WASHINGTON, Aug 3 - The U.S. Food and Drug Administration on Friday said it granted 10 drugmakers marketing approvals for the first generic forms of Singulair, the $5 billion-a-year asthma and allergy drug that is Merck & Co Inc's best-selling product.
WRAPUP 2-Generic drugmakers Mylan, Watson shares up on results
July 26 - Mylan Inc posted second-quarter profit well above Wall Street estimates, while rival Watson Pharmaceuticals Inc raised its full-year forecast after reporting quarterly results, and shares of the two generic drugmakers rose.
UPDATE 1-Mylan profit beats Wall Street view
July 26 - Mylan Inc posted a second-quarter profit above Wall Street estimates on Thursday, helped by sales of its EpiPen product for severe allergic reactions and its generic drugs in North America.
Mylan profit beats Wall Street view
July 26 - Mylan Inc posted second-quarter profit above Wall Street estimates on Thursday, helped by sales of its EpiPen product for severe allergic reactions and its generic drugs in North America.
Mylan, Teva settle row over sale of sleep drug
June 8 - Mylan Inc said it resolved disputes with Teva Pharmaceutical Industries Ltd over the sale of U.S. generic versions of the wide-selling sleep-disorder drug Provigil.
UPDATE 1-Mylan settles patent suit with Dainippon Sumitomo unit
May 29 - Mylan Inc settled a patent lawsuit with a unit of Dainippon Sumitomo Pharma Co, allowing the U.S. drug maker to continue selling a generic version of the Japanese company's drug for breathing difficulty.
UPDATE 1-Mylan settles patent suit over Sunovion's lung drug
May 24 - U.S. generic drug maker Mylan Inc settled a patent infringement suit with Sunovion Pharmaceuticals Inc, a unit of Dainippon Sumitomo Pharma Co, related to the Japanese drugmaker's bronchitis medicine Brovana.
BRIEF - Moody's raises Mylan Inc rating to Ba1
May 23 - Moody's raises Mylan Inc corporate family rating to Ba1 from Ba2
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $71.63 | -0.23 |
| GlaxoSmithKline plc (GSK.L) | 1,415.50p | -5.50 |
| Novartis AG (NOVN.VX) | CHF58.65 | -0.25 |
| Merck & Co., Inc. (MRK.N) | $46.50 | -0.53 |
| Abbott Laboratories (ABT.N) | $65.81 | -0.34 |
| Pfizer Inc. (PFE.N) | $25.55 | -0.21 |
| Eli Lilly & Co. (LLY.N) | $52.58 | -0.28 |
| Bristol Myers Squibb Co. (BMY.N) | $33.79 | -0.02 |
| Bristol Myers Squibb Co. (BMY_p.N) | $567.60 | 0.00 |
| Roche Holding Ltd. (ROG.VX) | CHF186.00 | -1.40 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$25.00
|
|
Trading Report for (MYL). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Standard & Poor's STARS Report
|
$115.00
|
|
Provider: Pechala's Reports
|
$10.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
